BVS

Bioventus Inc. Class A Common Stock (BVS)

Stock · NASDAQ · Health Care

$13.31as of 10/16/2026

Price chart

Open in TradingView

Active signals

Support Reject76.1%200 SMA Touch0.0%
Resistance level
$13.78
Industry
Medical/Dental Instruments

BVS Signal Track Record

How signals performed across all stocks →

What BVS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike38-3.3%42%
Bollinger Band Breakout26+6.5%62%
Bollinger Band Breakdown17-3.3%29%
200-Day Moving Average TouchActive now6+10.7%67%
Any 20-session window (baseline)+1.1%53%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About BVS

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to t…

Sector
Health Care
Industry
Medical/Dental Instruments
Employees
950

Fundamentals

1-day range
$13.69$13.91
Market cap
$1.17B
P/E (trailing)
21.32
P/E (forward)
15.01
EPS (trailing)
$0.78
Dividend yield
—
Beta
0.66
Avg. volume
596.5K
52-week range
$6.46$15.89
Next earnings: November 3, 2026 · EPS estimate $0.17confirmed

How Bioventus Inc. Class A Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$568.09MNet Income$22.73M (4%)SG&A$314.03M (55%)Cost of Revenue$179.93M (32%)Other$39.29M (7%)R&D$12.11M (2%)BVS

Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub

Gross Profit$388.16M(68%)
Operating Income$53.98M(10%)

Forecasts

5 analyst ratings

Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$19
+42.7%
Median
$18
+35.2%
Low
$15
+12.7%

Bioventus Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

  • BVS
    Bioventus Inc. Class A Common Stock
    $13.3
    ▼ 3.69%
    Market cap $1.17BP/E 21.32
    $6.46$15.89
  • IRMD
    iRadimed Corporation Common Stock
    $88.27
    ▼ 1.23%
    Market cap $1.17BP/E 49.82
    $71.34$107.9
  • DRTS
    Alpha Tau Medical Ltd. Ordinary Shares
    $12.29
    ▼ 6.61%
    Market cap $1.14BP/E —
    $3.43$15.79
  • PRCT
    PROCEPT BioRobotics Corporation Common Stock
    $17.57
    ▼ 3.20%
    Market cap $1.14BP/E —
    $16.67$38.11
  • TNDM
    Tandem Diabetes Care Inc. Common Stock
    $16.24
    ▼ 1.69%
    Market cap $1.29BP/E —
    $12.26$29.65
  • AORT
    Artivion Inc. Common Stock
    $21.78
    ▼ 0.41%
    Market cap $1.29BP/E 117.64
    $19.16$48.25
  • IART
    Integra LifeSciences Holdings Corporation Common Stock
    $13.21
    ▼ 2.37%
    Market cap $1.33BP/E —
    $8.7$20.49

P/E shows — for peers not currently carrying a live signal of their own.

Insider Activity

Insider Actions →
Acquired
418.7K
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
49.39M
Total value held
$444.00M
Institutional holders
151
Top holders this quarter
  • Unknown13.02M
  • Unknown6.94M
  • Unknown6.12M
  • Unknown3.13M
  • Unknown1.71M
  • Unknown1.54M
  • Unknown1.17M
  • Unknown988.4K
  • Unknown873.1K
  • Unknown671.1K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.